ReviewEuropean journal of pharmacology2020
Coronavirus diseases 2019: Current biological situation and potential therapeutic perspective.
Review in European journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05190016 (Development of a Multiplex BangasureTM RT-PCR Kit for the Detection of SARS-Corona Virus-2), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development of a Multiplex BangasureTM RT-PCR Kit for the Detection of SARS-Corona Virus-2
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Vitamin D: A key player in COVID-19 immunity and lessons from the pandemic to combat immune-evasive variants.Inflammopharmacology · 2024Review
- Advanced nanomedicines and immunotherapeutics to treat respiratory diseases especially COVID-19 induced thrombosis.World journal of clinical cases · 2024Review
- Ultrasensitive and fast detection of SARS-CoV-2 using RT-LAMP without pH-dependent dye.Functional & integrative genomics · 2024Article
- SARS-CoV-2 detection methods: A comprehensive review.Saudi journal of biological sciences · 2022Review
- Neurological complications of COVID-19 in children and the associated immunological responses.Journal of King Saud University. Science · 2022Review
- Multiplex real-time RT-PCR method for the diagnosis of SARS-CoV-2 by targeting viral N, RdRP and human RP genes.Scientific reports · 2022Article
- Article
- Review
- Therapeutic development by repurposing drugs targeting SARS-CoV-2 spike protein interactions by simulation studies.Saudi journal of biological sciences · 2021Article
- Diffuse functional brain disconnection syndrome in critically ill patients with COVID-19.Journal of infection and public health · 2021Article
- An in silico analysis of effective siRNAs against COVID-19 by targeting the leader sequence of SARS-CoV-2.Advances in cell and gene therapy · 2021Article
- A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19.European journal of pharmacology · 2021Review
- Science unites a troubled world: Lessons from the pandemic.European journal of pharmacology · 2021Article
- Validation and deployment of a direct saliva real-time RT-PCR test on pooled samples for COVID-19 surveillance testing.PloS one · 2021Article
- Article
- A case series report of hospitalized children with severe acute respiratory syndrome coronavirus-2 infection in Jinan, China.SAGE open medical case reports · 2020Article
- Immunity, Sex Hormones, and Environmental Factors as Determinants of COVID-19 Disparity in Women.Frontiers in immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus Disease 2019 (COVID-19) caused by a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in Wuhan, China at the end of December 2019. SARS-CoV-2 is a highly pathogenic zoonotic virus and closely related to the Severe Acute Respiratory Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The COVID-19 was declared as a global pandemic due to its high infectiousness, and worldwide morbidities and mortalities. The Chinese scientists at the start of the outbreak reported genome sequences, which made the characterization of glycoproteins and other structural proteins possible. Moreover, researchers across the world have widely focused on understanding basic biology, developing vaccines, and therapeutic drugs against the COVID-19. However, until now, no promising treatment options, as well as vaccines, are available. In this review, we have described SARS-CoV-2's genome, transmission, and pathogenicity. We also discussed novel potential therapeutic agents that can help to treat the COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.